These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31400471)

  • 1. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.
    Matt M; Duran C; Courjon J; Lotte R; Moing VL; Monnin B; Pavese P; Chavanet P; Khatchatourian L; Tattevin P; Cattoir V; Lechiche C; Illes G; Lacassin-Beller F; Senneville E; Dinh A;
    J Glob Antimicrob Resist; 2021 Jun; 25():341-345. PubMed ID: 33962065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.
    Guzek A; Suwalski G; Tomaszewski D; Rybicki Z
    J Cardiothorac Surg; 2018 Jan; 13(1):3. PubMed ID: 29304832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.
    Barnea Y; Lerner A; Aizic A; Navon-Venezia S; Rachi E; Dunne MW; Puttagunta S; Carmeli Y
    J Antimicrob Chemother; 2016 Feb; 71(2):460-3. PubMed ID: 26518048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-biofilm activity of dalbavancin against methicillin-resistant
    Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
    Koeth LM; DiFranco-Fisher JM; McCurdy S
    J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.